Summary
Drug transport and disposition are influenced by a non-specific and reversible drug binding to plasma and tissues proteins. Albumin and al acid glycoprotein are the most important transport proteins of the blood. Albumin possesses specific sites for acidic and basic drug binding and can interact with them in the plasma since a third site is trapped only by digoxin. Diseases and stress conditions induce conformational changes either in plasma or in tissue proteins by the synthesis of endogenous substances which can strong interfere with the amount of the free pharmacological effective drug ratio. This may affect the binding of drugs in target molecules inducing significant pharmacokinetic alterations. Stress conditions are associated with FFA increase in serum playing an antagonistic role with other acidic molecules (e.g. ampicillin) to the same binding site. The bounded drug is displaced and freer ratio is available to interact with various organ receptors leading to pharmacological effect enhancement and therefore to side effects manifestation such as seizures. Furthermore conjunctive tissues diseases, ageing, prolonged bleeding, starvation or diseases affecting protein profile, characterized by reduced total plasma proteins, followed by albumin decrease and lessen binding sites lead to more free drug availability enhancing its pharmacological effect. Increased a1-acid glycoprotein the acute phase protein as by heart infraction or liver morbidities (e.g CCl4 intoxication) mainly occupied from basic substances, in the case of cationic drug treatment resulted to the enhancement of the and consequently to pronounced effectiveness. In addition, renal failure reduced free fractions of many acidic drugs. It may be concluded that by narrowed therapeutic index of a medicine, and when drug/drug or drug/disease interactions are anticipated, drug monitoring seems to be necessary for its dosage adjustment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Benkestock K., Edlund P.O., Roeraade J. (2005): Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. Rapid Commun. Mass Spectrom., 19, 1637–1643.
Sudlow G., Birkett D.J., Wade D.N. (1975): The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol., 11, 824–832.
Wanwimolruk S., Birkett D.J., Brooks P.M. (1983): Structural requirements for drug binding to site II on human serum albumin. Mol. Pharmacol., 24, 458–463.
Frostell-Karlsson A., Remaeus A., Roos H., Andersson K., Borg P., Hämäläinen M., Karlsson R. (2000): Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem., 43, 1986–1992.
Olsen H., Andersen A., Nordbø A., Kongsgaard U.E., Børmer O.P. (2004): Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro. BMC Clin. Pharmacol., 4: 4.
Kragh-Hansen U. (1988): Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol. Pharmacol., 34, 160–171.
Prijovich Z.M., Leu Y.L., Roffler S.R. (2007): Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother Pharmacol., 60, 7–17.
Hu O.Y., Chu K.M., Liu H.S., Chiao S.F., Ho W., Ho S.T. (1993): Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. Acta Anaesthesiol. Scand., 37, 258–261.
Birkett D.J., Myers S.P., Sudlow G. (1977): Effects of fatty acids on two specific drug binding sites on human serum albumin. Mol. Pharmacol., 13, 987–992.
Vorum H., Honore B. (1996): Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J. Pharm. Pharmacol., 48, 870–875
Ivarsen R., Brodersen R. (1989): Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid. Dev. Pharmacol. Ther., 12, 19–29.
Sansom L.N., Evans A.M. (1995): What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf., 12, 227–233.
Simard J.R., Zunszain P.A., Hamilton J.A., Curry S. (2006): Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol., 361, 336–351.
Wosilait W.D., Ryan M.P. (1979): The effects of oleic acid, tolbutamide, and oxyphenbutazone on the binding of warfarin by human serum albumin. Res. Commun. Chem. Pathol. Pharmacol., 25, 577–584.
Huang B.X., Dass C., Kim H.Y. (2005): Probing conformational changes of human serum albumin due to unsaturated fatty acid binding by chemical cross-linking and mass spectrometry. Biochem. J., 387(Pt 3), 695–702.
Urien S., Albengres E., Zini R., Tillement J.P. (1982): Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem. Pharmacol., 31, 3687–3689.
Holladay J.W., Dewey M.J., Michniak B.B., Wiltshire H., Halberg D.L., Weigl P., Liang Z., Halifax K., Lindup W.E., Back D.J. (2001): Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab. Dispos., 29, 299–303.
Zhou H.H., Adedoyin A., Wilkinson G.R. (1990): Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin. Pharmacol. Ther., 48, 10–17.
Belpaire F.M., Bogaert M.G., Mussche M.M. (1977): Influence of acute renal failure on the protein binding of drugs in animals and in man. Eur. J. Clin. Pharmacol., 11, 27–32.
Henderson S.J., Lindup W.E. (1990): Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin, Biochem. Pharmacol., 40, 2543–2548.
Viani A., Rizzo G., Carrai M., Pacifici G.M. (1992): The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br. J. Clin. Pharmacol., 33, 299–304.
Cistola D.P., Small D.M. (1991): Fatty acid distribution in systems modeling the normal and diabetic human circulation. A13C nuclear magnetic resonance study. J. Clin. Invest., 87, 1431–1441.
Vorum H., Jorgensen H.R., Brodersen R. (1993): Variation in the binding affinity of warfarin and phenprocoumon to human serum albumin in relation to surgery. Eur. J. Clin. Pharmacol., 44, 157–162.
Vorum H., Fisker K., Honore B. (1997): Palmitate and stearate binding to human serum albumin. Determination of relative binding constants. J. Pept. Res., 49, 347–354.
Tsutsumi Y., Maruyama T., Takadate A., Goto M., Matsunaga H., Otagiri M (1999): Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm. Res., 16 916–923.
Sakai T., Yamasaki K., Sako T., Kragh-Hansen U., Suenaga A., Otagiri M. (2001): Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin, Pharm. Res., 18, 520–524.
Soltys B.J., Hsia J.C. (1978): Steroid modulation of human serum albumin binding properties. A spin label study. J. Biol. Chem., 253, 4266–4269.
Bhattacharya A.A., Curry S., Franks N.P. (2000): Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J. Biol. Chem., 275, 38731–38738.
Petitpas I., Grune T., Bhattacharya A.A., Curry S. (2001): Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol., 314, 955–960.
Petersen C.E., Ha C.E., Curry S., Bhagavan N.V. (2002): Probing the structure of the warfarin-binding site on human serum albumin using site-directed mutagenesis. Proteins, 47, 116–125.
Tsopanakis C., Tesserommatis C. (1991): Cold swimming stress: effects on serum lipids, lipoproteins and LCAT activity in male and female rats. Pharmacol. Biochem. Behav., 38, 813–816.
Tesserommatis C., Tsopanakis C., Varonos D. (1988): Changes in serum lipids with the presence of various factors. Beitr. Infusionsther., 23, 195–197.
Saranteas T., Tesseromatis C., Potamianou A., Mourouzis C., Varonos D. (2002): Stress-induced lidocaine modification in serum and tissues. Eur. J. Drug Metabol. Pharmacokinet., 27, 229–232.
Tesseromatis C., Trichilis A., Tsivos E., Messari J., Triantaphyllidis H., Varonos D.D. (2001): Does stress influence ampicillin concentration in serum and tissues? Eur. J. Drug Metab01. Pharmacokinet., 26, 167–171.
Tesserommatis C., Tsopanakis C., Symeonoglou G., Loukissa M., Kouvarou E., Varonos D.D. (1996): How harmless is FFA enhancement? Eur. J. Drug Metabol. Pharmacokinet., 21, 213.
Trichilis A., Saranteas T., Potamianou A., Mourouzis C., Tesseromatis C. (2003): Quinolone levels in serum and maxillofacial tissues under ibuprofen co-administration following surgical trauma. J. Musculoskelet. Neuronal Interact., 3, 170–175.
Trichilis A., Tesserommatis C., Varonos D. (2000): Changes in serum levels of quinolones in rats under the influence of experimental trauma. Eur. J. Drug Metabol. Pharmacokinet., 25, 73–78.
Saranteas T., Zotos N., Lolis E., Stranomiti J., Mourouzis C., Chantzi C., Tesseromatis C. (2005): Mechanisms of ketamine action on lipid metabolism in rats. Eur. J. Anaesthesiol., 22, 222–226.
Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. (2005): Structural basis of the drugbinding specificity of human serum albumin. J. Mol. Biol. 353, 38–52.
Tigka E., Daskala I., Rallis G., Anagnostopoulou S., Tesseromatis C. (2005): Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats. Eur. J. Drug Metabol. Pharmacokinet., 30, 235–241.
Saranteas T., Zotos N., Chantzi C., Mourouzis C., Rallis G., Anagnostopoulou S., Tesseromatis C. (2005): Ketamine-induced changes in metabolic and endocrine parameters of normal and 2-kidney 1-clip rats. Eur. J. Anaesthesiol., 22, 875–878.
Tillement J.P., Lhoste F., Giudicelli J.F. (1978): Diseases and drug protein binding. Clin. Pharmacokinet., 3, 144–154.
Perucca E. (1980): Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther. Drug Monit., 2, 331–344.
Tsivou E., Melakopoulos I., Kotsiou A., Anagnostopoulou S., Tesseromatis C. (2005): Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after coadministration of ibuprofen. Eur. J. Drug Metabol. Pharmacokinet., 30, 171–174.
Melakopoulos I., Tesseromatis C., Saranteas T., Karabinos I. (1997): Changes of serum and tissue amoxicillin levels following chlorpromazine administration in rats. Anaerobe, 3, 103–105.
Saranteas T., Mourouzis C., Dannis C., Alexopoulos C., Lolis E., Tesseromatis C. (2004): Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J. Oral Maxillofac. Surg., 62, 858–862.
Kotsiou A., Tsamouri M., Anagnostopoulou S., Tzivras M., Vairactaris E., Tesseomatis C. (2006): H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage. Eur. J. Drug Metabol. Pharmacokinet., 31, 97–101.
Tesseromatis C., Kotsiou A., Tsagataki M., Tigka E., Vovou J., Alevizou A., Perisanidis C., Saranteas T., Karakitsos D., Karabinis A., Kostopanagiotou G. (2007): In vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction? Eur J Drug Metabol. Pharmacokinet., 32, 213–217.
Fichtl B., Gerdsmeier W. (1981): Increased plasma protein binding of propranolol in rabbits with acute renal failure. Life Sciences, 28, 31–35.
Fichtl B. (1990): The influence of renal failure on-drug binding in plasma and tissues. Nieren-und Hochdruckkrankheiten, 19, 447–449.
Bree F., Houin G., Barre J., Moretti J.L., Wirquin V., Tillement J.P. (1986): Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clin. Pharmacokinet., 11, 336–342.
Fichtl B., Nieciecki A., Walter K. (1991): Tissue binding versus plasma binding of drugs: General Principles and Pharmacokinetic Consequences. Adv. Drug Res., 20, 117–166.
Habig W.H., Pabst M.J., Fleischner G., Gatmaitan Z., Arias I.M., Jakoby W.B. (1974): The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc. Natl. Acad. Sci. USA, 71, 3879–3882.
Saranteas T., Mourouzis C., Koumoura F., Tesseromatis C. (2003): Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J. Oral Maxillofac. Surg., 61, 604–607.
Tesseromatis C. Saranteas T., Chatzijanni E., Anagnostopoulou S., Cotsiou A., Chantzi C. (2003): Modifications of clonidine binding to rabbit liver protein under the influence of non-steroid-anti-inflammatory drugs in vitro. Eur. J. Drug Metabol. Pharmacokinet., 28, 245–247.
Fichtl B., Kurz H. (1978): Binding of drugs to human muscle. Eur. J. Clin. Pharmacol., 14, 335–340.
Tesseromatis C., Fichtl B., Kurz H. (1987): Binding of nonsteroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro. Eur. J. Drug Metabol. Pharmacokinet., 12, 161–167.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tesseromatis, C., Alevizou, A. The role of the protein-binding on the mode of drug action as well the interactions with other drugs. Eur. J. Drug Metabol. Pharmacokinet. 33, 225–230 (2008). https://doi.org/10.1007/BF03190876
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190876